statistiche ricercatore

statistiche per SARTORE BIANCHI, ANDREA

Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 2463
EU - Europa 1935
AS - Asia 1257
OC - Oceania 104
SA - Sud America 77
AF - Africa 42
Continente sconosciuto - Info sul continente non disponibili 18
Totale 5896
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2372
IT - Italia 776
CN - Cina 707
DE - Germania 299
GB - Regno Unito 277
FR - Francia 158
JP - Giappone 120
KR - Corea 104
AU - Australia 91
CA - Canada 72
IN - India 69
NL - Olanda 61
TW - Taiwan 57
ES - Italia 52
BR - Brasile 39
HK - Hong Kong 33
NO - Norvegia 30
RO - Romania 30
TR - Turchia 30
CZ - Repubblica Ceca 28
RU - Federazione Russa 28
BE - Belgio 27
SE - Svezia 25
ZA - Sudafrica 23
CH - Svizzera 21
ID - Indonesia 21
PT - Portogallo 21
IL - Israele 19
CL - Cile 17
SG - Singapore 17
UA - Ucraina 15
AT - Austria 13
IE - Irlanda 13
NZ - Nuova Zelanda 13
GR - Grecia 12
IR - Iran 12
MY - Malesia 12
TH - Thailandia 12
AP - ???statistics.table.value.countryCode.AP??? 11
MX - Messico 11
DK - Danimarca 9
PE - Perù 9
FI - Finlandia 8
JO - Giordania 7
SK - Slovacchia (Repubblica Slovacca) 7
CO - Colombia 6
HU - Ungheria 6
PL - Polonia 6
AR - Argentina 5
EG - Egitto 5
EU - Europa 5
IQ - Iraq 5
PK - Pakistan 5
KW - Kuwait 4
VN - Vietnam 4
BA - Bosnia-Erzegovina 3
DO - Repubblica Dominicana 3
DZ - Algeria 3
LK - Sri Lanka 3
MA - Marocco 3
QA - Qatar 3
RS - Serbia 3
SA - Arabia Saudita 3
A1 - ???statistics.table.value.countryCode.A1??? 2
BG - Bulgaria 2
GE - Georgia 2
KE - Kenya 2
PH - Filippine 2
TN - Tunisia 2
AE - Emirati Arabi Uniti 1
AM - Armenia 1
BD - Bangladesh 1
BM - Bermuda 1
CR - Costa Rica 1
CY - Cipro 1
ET - Etiopia 1
GT - Guatemala 1
HR - Croazia 1
IM - Isola di Man 1
KH - Cambogia 1
LB - Libano 1
LT - Lituania 1
LV - Lettonia 1
NE - Niger 1
PA - Panama 1
PR - Porto Rico 1
SD - Sudan 1
SI - Slovenia 1
SN - Senegal 1
UY - Uruguay 1
Totale 5896
Salva come PNG Salva come JPEG
Città #
Milan 428
Fairfield 344
Woodbridge 202
Seattle 197
Buffalo 178
Houston 165
Ashburn 128
Cambridge 125
Ann Arbor 98
Shanghai 98
Wilmington 90
Beijing 88
Wuhan 61
Guangzhou 55
Tokyo 42
Taipei 36
Nanjing 34
Nürnberg 31
Chengdu 30
Torino 30
Hangzhou 27
Ottawa 26
Seoul 26
Las Vegas 23
London 22
Munich 22
Shenyang 22
Changchun 21
Muizenberg 20
Oslo 20
Phoenix 20
Clearwater 19
Jakarta 19
New York 19
Berlin 16
Central District 16
Rome 16
Southend 16
University Park 16
Changsha 14
Baltimore 13
Chicago 12
Los Angeles 12
Rochester 12
Heidelberg 11
Padova 11
Amsterdam 10
Boston 10
Leawood 10
Lima 10
Melbourne 10
New Delhi 10
Newbury Park 10
Singapore 10
Hefei 9
Mumbai 9
San Diego 9
San Francisco 9
San Mateo 9
Toronto 9
Barcelona 8
Brisbane 8
Dallas 8
Darmstadt 8
Duncan 8
Madrid 8
Mountain View 8
Tianjin 8
Birmingham 7
Chongqing 7
Fontenay-sous-bois 7
Fuzhou 7
Istanbul 7
Milpitas 7
Nanchang 7
Nashville 7
Nutley 7
Philadelphia 7
Riva 7
San Jose 7
Santiago 7
Zhengzhou 7
Athens 6
Bangalore 6
Bucharest 6
Dundee 6
Oxford 6
Paris 6
Pittsburgh 6
Porth 6
Rotterdam 6
Salt Lake City 6
Serra 6
Shaoxing 6
Suzhou 6
Sydney 6
Toulouse 6
Tucson 6
Utrecht 6
Wenzhou 6
Totale 3335
Salva come PNG Salva come JPEG
Nome #
Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer, file 509086 1474
Liquid biopsy for rectal cancer: a systematic review, file 1300031 492
The molecular landscape of colorectal cancer cell lines unveils clinically actionable kinase targets, file 481585 455
Mutations of KRAS and BRAF in primary and matched metastatic sites of colorectal cancer, file 509105 431
A validated prognostic classifier for V600EBRAF-mutated metastatic colorectal cancer : the 'BRAF BeCool' study, file 1280213 228
Third- or Later-line Therapy for Metastatic Colorectal Cancer : Reviewing Best Practice, file 1201003 195
Safety and antitumor activity of the multitargeted pan-TRK, ROS1, and ALK inhibitor entrectinib : combined results from two phase I trials (ALKA-372-001 and STARTRK-1), file 970760 179
Early-onset colorectal cancer in young individuals, file 1211176 163
Digital PCR quantification of MGMT methylation refines prediction of clinical benefit from alkylating agents in glioblastoma and metastatic colorectal cancer, file 481528 130
Dynamic molecular analysis and clinical correlates of tumor evolution within a phase II trial of panitumumab-based therapy in metastatic colorectal cancer, file 966422 120
NTRK gene fusions as novel targets of cancer therapy across multiple tumour types, file 665103 119
Negative hyperselection of patients with RAS and BRAF wild-type metastatic colorectal cancer who received panitumumab-based maintenance therapy, file 1384064 118
Prognostic significance of K-Ras mutation rate in metastatic colorectal cancer patients, file 480425 118
Radiological imaging markers predicting clinical outcome in patients with metastatic colorectal carcinoma treated with regorafenib: post hoc analysis of the CORRECT phase III trial (RadioCORRECT study), file 1052971 115
Sequential HER2 blockade as effective therapy in chemorefractory, HER2 gene-amplified, RAS wild-type, metastatic colorectal cancer: learning from a clinical case, file 969065 114
Increased incidence of colon cancer among individuals younger than 50 years : a 17 years analysis from the cancer registry of the municipality of Milan, Italy, file 1231568 103
Pooled Analysis of Clinical Outcome of Patients with Chemorefractory Metastatic Colorectal Cancer Treated within Phase I/II Clinical Studies Based on Individual Biomarkers of Susceptibility : a Single-Institution Experience, file 966361 90
Phase II open-label study to assess efficacy and safety of lenalidomide in combination with cetuximab in kras-mutant metastatic colorectal cancer, file 482463 88
Multi-determinants analysis of molecular alterations for predicting clinical benefit to EGFR-targeted monoclonal antibodies in colorectal cancer, file 688493 88
Acquired RAS or EGFR mutations and duration of response to EGFR blockade in colorectal cancer, file 1016542 87
Challenging chemoresistant metastatic colorectal cancer: Therapeutic strategies from the clinic and from the laboratory, file 1396048 81
The right chance for temozolomide in metastatic colorectal cancer?, file 1193830 79
Targeting the human epidermal growth factor receptor 2 (HER2) oncogene in colorectal cancer, file 1032632 78
Reliance upon ancestral mutations is maintained in colorectal cancers that heterogeneously evolve during targeted therapies, file 1102082 76
Tropomyosin receptor kinase (TRK) biology and the role of NTRK gene fusions in cancer, file 1389529 76
Mutation-enrichment next-generation sequencing for quantitative detection of KRAS mutations in urine cell-free DNA from patients with advanced cancers, file 967143 73
The Evolving Biomarker Landscape for Treatment Selection in Metastatic Colorectal Cancer, file 1310473 69
Clonal evolution andKRAS-METcoamplification during secondary resistance to EGFR-targeted therapy in metastatic colorectal cancer, file 970778 63
Bortezomib inhibits nuclear factor-κB-dependent survival and has potent in vivo activity in mesothelioma, file 1201027 61
High Circulating Methylated DNA Is a Negative Predictive and Prognostic Marker in Metastatic Colorectal Cancer Patients Treated With Regorafenib, file 1356267 58
Whole exome sequencing analysis of urine trans-renal tumour DNA in metastatic colorectal cancer patients, file 1347993 41
Gemcitabine and Oxaliplatin in the Treatment of Patients with Immunotherapy-Resistant Advanced Renal Cell Carcinoma: Final Results of a Single-Institution Phase II Study, file 1201288 38
Concurrent small cell transformation and emergence of trans-C797S and T790M mutations under sequential treatment with EGFR inhibitors in lung adenocarcinoma, file 1401967 33
The quest for improving treatment of cancer of unknown primary (CUP) through molecularly-driven treatments: a systematic review, file 1473630 32
Correction: Sequential HER2 blockade as effective therapy in chemorefractory, HER2 gene-amplified, RAS wild-type, metastatic colorectal cancer: Learning from a clinical case (ESMO Open (2018) 3 (e000299) DOI: 10.1136/esmoopen-2017-000299), file 1402969 24
CDK4/6 Inhibitors in Breast Cancer Treatment: Potential Interactions with Drug, Gene, and Pathophysiological Conditions, file 1555301 18
Impact of inter-reader contouring variability on textural radiomics of colorectal liver metastases, file 1632846 17
Maintenance Therapy with Panitumumab Alone vs Panitumumab Plus Fluorouracil-Leucovorin in Patients with RAS Wild-Type Metastatic Colorectal Cancer: A Phase 2 Randomized Clinical Trial, file 1266896 14
Assessment of a HER2 scoring system for colorectal cancer : results from a validation study, file 480370 13
The genomic landscape of response to EGFR blockade in colorectal cancer, file 480448 12
Prognostic significance of K-Ras mutation rate in metastatic colorectal cancer patients, file 559301 11
Overcoming dynamic molecular heterogeneity in metastatic colorectal cancer : multikinase inhibition with regorafenib and the case of rechallenge with anti-EGFR, file 1015009 10
Tracking a CAD-ALK gene rearrangement in urine and blood of a colorectal cancer patient treated with an ALK inhibitor, file 966988 9
Linitis Plastica of the Rectum As a Clinical Presentation of Metastatic Lobular Carcinoma of the Breast, file 650595 8
Oxaliplatin Immune-Induced Syndrome Occurs With Cumulative Administration and Rechallenge : Single Institution Series and Systematic Review Study, file 1014267 7
Amplification of the MET receptor drives resistance to anti-EGFR therapies in colorectal cancer, file 489305 7
Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients, file 559310 7
Radiomics predicts response of individual HER2-amplified colorectal cancer liver metastases in patients treated with HER2-targeted therapy, file 1552650 6
Inactivation of DNA repair triggers neoantigen generation and impairs tumour growth, file 965293 6
Lipid-lowering therapy of everolimus-related severe hypertriglyceridaemia in a pancreatic neuroendocrine tumour (pNET), file 966392 6
Discovery of methylated circulating DNA biomarkers for comprehensive non-invasive monitoring of treatment response in metastatic colorectal cancer, file 967256 6
Lipid-lowering therapy of everolimus-related severe hypertriglyceridaemia in a pancreatic neuroendocrine tumour (pNET), file 1017555 5
Mutation-enrichment next-generation sequencing for quantitative detection of KRAS mutations in urine cell-free DNA from patients with advanced cancers, file 1018773 5
Plasma HER2 (ERBB2) copy number predicts response to HER2-targeted therapy in metastatic colorectal cancer, file 1193679 5
Chemotherapy-induced myasthenic crisis in thymoma treated with primary chemotherapy with curative intent on mechanical ventilation: a case report and review of the literature, file 1693156 5
Acquired resistance to EGFR-targeted therapies incolorectal cancer, file 481642 5
Blockade of EGFR and MEK intercepts heterogeneous mechanisms of acquired resistance to Anti-EGFR therapies in colorectal cancer, file 489250 5
Detection of circulating tumor DNA in early- and late-stage human malignancies, file 489265 5
Somatic mutation of EGFR catalytic domain and treatment with gefitinib in colorectal cancer, file 509266 5
Digital PCR assessment of MGMT promoter methylation coupled with reduced protein expression optimises prediction of response to alkylating agents in metastatic colorectal cancer patients, file 966451 5
Oxaliplatin Immune-Induced Syndrome Occurs With Cumulative Administration and Rechallenge : Single Institution Series and Systematic Review Study, file 968893 5
Parallel Evaluation of Circulating Tumor DNA and Circulating Tumor Cells in Metastatic Colorectal Cancer, file 1014733 4
A subset of colorectal cancers with cross-sensitivity to olaparib and oxaliplatin, file 1381193 4
BRAF codons 594 and 596 mutations identify a new molecular subtype of metastatic colorectal cancer at favorable prognosis, file 481492 4
Effects of Cancer Therapy Targeting Vascular Endothelial Growth Factor Receptor on Central Blood Pressure and Cardiovascular System, file 489201 4
Promoter CpG island hypermethylation of the DNA repair enzyme MGMT predicts clinical response to dacarbazine in a phase II study for metastatic colorectal cancer, file 489312 4
Standardisation of EGFR FISH in colorectal cancer: Results of an international interlaboratory reproducibility ring study, file 507431 4
Acquired resistance to the TRK inhibitor entrectinib in colorectal cancer, file 549420 4
Digital PCR quantification of MGMT methylation refines prediction of clinical benefit from alkylating agents in glioblastoma and metastatic colorectal cancer, file 559746 4
Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES) : a proof-of-concept, multicentre, open-label, phase 2 trial, file 676532 4
Molecular landscape of acquired resistance to targeted therapy combinations in BRAF mutant colorectal cancer, file 676893 4
Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab, file 967409 4
Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer : a retrospective consortium analysis, file 967414 4
Human epidermal growth factor receptor 2 as amolecular biomarker formetastatic colorectal cancer, file 968713 4
Tumor MGMT promoter hypermethylation changes over time limit temozolomide efficacy in a phase II trial for metastatic colorectal cancer, file 968799 4
ALK, ROS1, and NTRK Rearrangements in Metastatic Colorectal Cancer, file 996488 4
Effect of KRAS and BRAF Mutations on Survival of Metastatic Colorectal Cancer After Liver Resection : a Systematic Review and Meta-Analysis, file 1018737 3
Combined low densities of FoxP3+ and CD3+ tumor-infiltrating lymphocytes identify stage II colorectal cancer at high risk of progression, file 1193796 3
Radiologic and Genomic Evolution of Individual Metastases during HER2 Blockade in Colorectal Cancer, file 1193852 3
A comprehensive PDX gastric cancer collection captures cancer cell intrinsic transcriptional MSI traits, file 1359034 3
The Evolving Biomarker Landscape for Treatment Selection in Metastatic Colorectal Cancer, file 1359227 3
Resistance to Anti-EGFR therapy in colorectal cancer: From heterogeneity to convergent evolution, file 481625 3
Translational challenges from the 2014 Gastrointestinal Cancers Symposium : Toward a true tailored therapy through effective research, file 482127 3
Epigenetic inactivation of the BRCA1 interactor SRBC and resistance to oxaliplatin in colorectal cancer, file 482143 3
KRAS gene amplification in colorectal cancer and impact on response to EGFR-targeted therapy, file 482161 3
Acquired resistance to the TRK inhibitor entrectinib in colorectal cancer, file 489182 3
Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer, file 489321 3
Novel CAD-ALK gene rearrangement is drugable by entrectinib in colorectal cancer, file 507386 3
BRAF codons 594 and 596 mutations identify a new molecular subtype of metastatic colorectal cancer at favorable prognosis, file 559302 3
The genomic landscape of response to EGFR blockade in colorectal cancer, file 559385 3
Parallel Evaluation of Circulating Tumor DNA and Circulating Tumor Cells in Metastatic Colorectal Cancer, file 967059 3
Therapeutic implications of resistance to molecular therapies in metastatic colorectal cancer, file 967351 3
Effect of KRAS and BRAF Mutations on Survival of Metastatic Colorectal Cancer After Liver Resection : a Systematic Review and Meta-Analysis, file 969048 3
Tumor MGMT promoter hypermethylation changes over time limit temozolomide efficacy in a phase II trial for metastatic colorectal cancer, file 1015310 2
TRKA expression and NTRK1 gene copy number across solid tumours, file 1193806 2
Treatment sequencing in metastatic colorectal cancer, file 1200997 2
Plasticity of resistance and sensitivity to anti-epidermal growth factor receptor inhibitors in metastatic colorectal cancer, file 1310481 2
Capecitabine and Temozolomide versus FOLFIRI in RAS-Mutated, MGMT-Methylated Metastatic Colorectal Cancer, file 1384056 2
Adaptive mutability of colorectal cancers in response to targeted therapies, file 1385122 2
KRAS mutations and anti-epidermal growth factor receptor therapy in colorectal cancer with lymph node metastases, file 1391110 2
Totale 6121
Salva come PNG Salva come JPEG
Categoria #
all - tutte 6164
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 6164
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2015/201682 0000 00 00 664111
2016/2017120 701024 01 32 534718
2017/2018733 28376141 4429 5061 601669165
2018/20191290 77788176 6967 8371 103139240206
2019/20202267 187159143170 189183 197213 252194172208
2020/20211609 154189194179 246212 224188 23000
Totale 6164
 
 
 
Powered by IRIS-about IRIS-Utilizzo dei cookie
Logo CINECA  Copyright © 2021